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Novelty and impact: The association between cigarette smoking and ovarian cancer survival 
is unclear. In the largest study to date including 9,114 women diagnosed with ovarian cancer, 
we observed that smokers had worse survival compared with women who had never smoked. 
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The associations were most pronounced for mucinous and serous tumours, among women 
with localised disease and with longer follow-up since ovarian cancer diagnosis. Hence, this 
study identifies cigarette smoking as a modifiable factor associated with ovarian cancer 
survival. 
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ABSTRACT  
 
Cigarette smoking is associated with an increased risk of developing mucinous ovarian 
tumours but whether it is associated with ovarian cancer survival overall or for the different 
histotypes is unestablished. Furthermore, it is unknown whether the association between 
cigarette smoking and survival differs according to strata of ovarian cancer stage at diagnosis. 
In a large pooled analysis, we evaluated the association between various measures of cigarette 
smoking and survival among women with epithelial ovarian cancer. We obtained data from 
19 case-control studies in the Ovarian Cancer Association Consortium (OCAC), including 
9,114 women diagnosed with ovarian cancer. Cox regression models were used to estimate 
adjusted study-specific hazard ratios (HRs), which were combined into pooled hazard ratios 
(pHR) with corresponding 95% confidence intervals (CIs) under random effects models. 
Overall, 5,149 (57%) women died during a median follow-up period of 7.0 years. Among 
women diagnosed with ovarian cancer, both current (pHR = 1.17, 95% CI: 1.08-1.28) and 
former smokers (pHR = 1.10, 95% CI: 1.02-1.18) had worse survival compared with never 
smoking women. In histotype-stratified analyses, associations were observed for mucinous 
(current smoking: pHR = 1.91, 95% CI: 1.01-3.65) and serous histotypes (current smoking: 
pHR = 1.11, 95% CI: 1.00-1.23; former smoking: pHR = 1.12, 95% CI: 1.04-1.20). Further, 
our results suggested that current smoking has a greater impact on survival among women 
with localised than disseminated disease. The identification of cigarette smoking as a 
modifiable factor associated with survival has potential clinical importance as a focus area to 
improve ovarian cancer prognosis. 
 
INTRODUCTION 
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Ovarian cancer is the most deadly gynaecological disease in the Western World, causing more 
than 150,000 deaths worldwide in 2012.
1
 Currently, no effective technique of routine 
population screening exists and, because ovarian cancer has non-specific symptoms,
2
 up to 
80% of all ovarian cancers are diagnosed at advanced stages.
3
 As a consequence, women with 
ovarian cancer have a poor prognosis, with an overall 5-year survival of only around 40%.
3
  
 
Factors known to play a role in ovarian cancer survival include age, stage and grade, but these 
are unmodifiable.
4,5
 Thus, identification of modifiable factors that potentially improve 
prognosis for women diagnosed with ovarian cancer may have clinical and public health 
importance. However, little is known about modifiable lifestyle factors in ovarian cancer but 
in a recent paper, Nagle et al. found that higher BMI was associated with adverse survival 
among women with ovarian cancer.
6
  
 
Even though the number of female smokers has declined in most parts of the Western world, 
cigarette smoking is still very common in many countries and it has been estimated that 
nearly 180 million adult women worldwide smoke cigarettes daily.
7
 Cigarette smoking is 
known to affect the risk of developing epithelial ovarian cancer. The association differs by 
histotype, reflecting their different aetiologies, and the strongest association is observed for 
mucinous ovarian tumours.
8-11
 Further, smoking has been found to correlate with survival for 
several malignancies including lung, breast and laryngeal cancer,
12-14
 but only a few studies 
have investigated the association between cigarette smoking and epithelial ovarian cancer 
survival and the results have been inconclusive.
15-21
 Four studies found that cigarette smoking 
was associated with worse survival,
15-18
 whereas three studies found no association.
19-21
 
However, the results from most previous studies are based on small numbers of participants 
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(n = 61-1,997 women), only one of the studies performed separate analyses by histotype,
18
 
and only two of the studies investigated progression-free survival.
17,18
  
 
By use of data from 19 case-control studies participating in the Ovarian Cancer Association 
Consortium (OCAC), the aim of this study was to investigate the prognostic impact of pre-
diagnostic cigarette smoking on epithelial ovarian cancer survival, both overall and according 
to histotype. We furthermore investigated whether the association between smoking status 
and survival differed according to strata of stage of ovarian cancer at diagnosis (localised vs 
advanced stage). 
 
MATERIALS AND METHODS  
 
OCAC, which has been described in detail elsewhere,
22
 is an international collaboration 
founded in 2005. For the present analyses, 19 case-control studies provided data on cigarette 
smoking, potential confounders and clinical follow-up information (Table 1).
23-41
  
 
Using standardised formats, data from each OCAC study were centrally harmonised. All data 
were checked for internal consistency and, where necessary, clarification was provided by the 
original investigators. In the present study, women diagnosed with fallopian tube or peritoneal 
cancer as well as women diagnosed with borderline ovarian tumors were not considered for 
analyses. Consequently, the initial study population consisted of women diagnosed with 
epithelial ovarian cancers only (n = 14,150). From these, we excluded women with missing 
data on vital status or survival time (n = 1,364), smoking status (n = 1,973), age (n = 3), 
race/ethnicity (n = 20), tumour stage (n = 478) and grade (n = 1,198), leaving 9,114 women 
diagnosed with epithelial ovarian cancer eligible for analyses. Of these, there were 5,455 
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serous ovarian tumours (5,014 high-grade and 441 low-grade serous ovarian tumours), 611 
mucinous, 1,473 endometrioid, 600 clear cell ovarian tumours, and 975 with other types of 
epithelial ovarian tumours. All individual studies included in OCAC had institutional review 
board and/or ethics committee approval and all study participants provided informed consent.  
 
Assessment of cigarette smoking 
Information on use of tobacco products other than cigarettes was limited to a few studies. 
Therefore, this study only addressed the prognostic impact of pre-diagnostic cigarette 
smoking on epithelial ovarian cancer survival. Information on cigarette smoking was obtained 
through self-administered questionnaires or in-person interviews and assessment of current 
and former smoking related either to date of diagnosis or interview, or one year prior to this 
depending on the study. We obtained information on smoking status prior to diagnosis (never, 
former or current), cigarette consumption (average number of cigarettes per day), total 
duration of smoking (years) and time since smoking cessation (years). Among the case-
control studies included, various definitions were used to classify women who had smoked. 
Some studies used a definition of at least 100 cigarettes smoked during the lifetime (AUS,
28
 
CON,
40
 DOV,
39
 JPN,
26
 MAY,
27
 NCO,
30
 NEC,
31
 POL,
33
 TBO,
41
 and UCI
37
) whereas other 
studies used daily smoking for a period of 3, 6 or 12 months (GER,
29
 HAW,
25
 HOP,
38
 NJO,
23
 
SEA,
35
 STA,
34
 UKO,
32
 and USC
36
) or self-report of smoking without further specification 
(MAL
24
).  
 
Covariate and clinical data 
From all 19 studies included, we obtained information about the following covariates 
associated with smoking and/or survival: age at diagnosis, race/ethnicity (non-Hispanic 
White, Hispanic White, Black, Asian or others, including unknown race), tumour grade (well, 
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moderately or poorly differentiated, or undifferentiated) and tumour stage at diagnosis. In the 
OCAC data, tumour stage was classified from a harmonised summary stage variable based on 
the International Federation of Gynaecology and Obstetrics (FIGO) staging system and the 
Surveillance, Epidemiology, and End Results (SEER) staging manuals and categorised as: 
localised, regional, distant or unknown. Information on FIGO and SEER stage was obtained 
by each OCAC study from a variety of sources including medical records, pathology reports, 
institutional databases, hospital tumour boards and cancer registries. Furthermore, 15 studies 
(all studies but SEA, STA, TBO and UKO) had information on recent BMI (one or five years 
prior to ovarian cancer, depending on the study) and 17 studies (all studies but JPN and TBO) 
provided information on level of education (≤high school vs >high school). Information on 
residual disease remaining after primary surgery was available from seven studies (AUS, 
HAW, JPN, MAL, MAY, NCO and NEC). In the common OCAC data set, residual disease 
was defined as the maximum dimension of disease remaining after primary surgery and 
categorised as: no macroscopic disease, macroscopic disease ≤1 cm, macroscopic disease >1 
cm and ≤2 cm, macroscopic disease >2 cm, macroscopic disease (size unknown), tumour not 
resected or unknown. In the analysis, residual disease was categorised as a dichotomous 
variable (no macroscopic disease present vs macroscopic disease present).  
 
Each study reported vital status and survival time and follow-up information was obtained 
from a variety of data sources including medical record review, patient contact, linkage with 
state cancer registries, use of the SEER registry and death-record databases. Overall survival 
time was calculated from date of diagnosis or date of study recruitment whichever came last, 
until date of death from any cause or, for living patients, date of last follow-up. Cause of 
death data was only available from seven studies (AUS, HAW, JPN, MAL, MAY, NCO and 
NEC) corresponding to 968 women of the 5,149 women who had died (19%). In the present 
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study, death due to an ovarian cancer diagnosis was defined as death due to progression of the 
disease. Among the women for whom cause of death data were available, the vast majority 
(94%) had died from ovarian cancer. Thus, all-cause mortality was used as the primary 
outcome in these analyses. Further, for the seven studies where data were available (AUS, 
HAW, JPN, MAL, MAY, NCO and NEC), progression-free survival time was calculated 
from date of diagnosis to date of documented clinical (e.g. ascites), biochemical (i.e., CA125) 
or radiological disease progression (CT scan), date of death or date of last follow-up for 
patients who had not progressed. For all 19 studies included, the time-period from date of 
diagnosis to date of study recruitment was available and left truncation at recruitment was 
used in all analyses to account for time elapsed between date of diagnosis and date of study 
recruitment, in order to reduce the likelihood of survivorship bias arising from the exclusion 
of eligible women who had died before recruitment. 
 
Statistical analysis  
Associations between the various variables of smoking and survival were analysed using a 
two-stage approach.
42
 In stage one, adjusted study-specific hazard ratios (HRs) and 
corresponding standard errors were obtained from Cox regression models with time since 
diagnosis as the underlying time scale. Smoking status was included as a categorical variable 
(never, former or current), whereas “cigarette consumption”, “duration of smoking” and “time 
since smoking cessation” were parameterised both as categorical and as continuous variables. 
Each categorical variable was categorised into ordinal groups with never smokers as the 
reference group. The associations between the continuous variables “cigarette consumption”, 
“duration of smoking” and ovarian cancer survival were evaluated among ever smokers 
(former or current smokers), whereas the association between “time since smoking cessation” 
and survival was evaluated among former smokers only. All study-specific analyses were 
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adjusted for age (continuous, included as a linear variable), tumour stage (localised, regional 
or distant), tumour grade (well, moderately or poorly differentiated or undifferentiated) and 
race/ethnicity (non-Hispanic White, Hispanic White, Black, Asian or other, including 
unknown race). Not all studies had data on BMI (continuous, per 5 kg/m
2
), level of education 
(≤high school vs >high school) or residual disease (no macroscopic disease present vs 
macroscopic disease present) and these variables were therefore only included as adjustment 
factors in a subset of studies in additional statistical models.  
 
In stage two, the study-specific estimates were combined by a random-effects inverse 
variance-weighted univariate meta-analysis into a pooled hazard ratio (pHR) with 
corresponding 95% CIs.
43
 For all analyses, individual studies were included in the meta-
analysis only if the following two requirements were met: 1) at least five observations with 
data on all covariates were available and 2) there were at least one observation with an event, 
i.e. death (or progression for the analyses on progression free survival). Statistical 
heterogeneity among studies was evaluated using the Cochran Q and I
2 
statistics, but as only 
very little and non-consistent evidence of heterogeneity was observed in the analyses, 
potential sources of heterogeneity were not investigated further.  
 
Analyses for the associations between smoking and overall survival were also conducted 
separately for the various standard histotypes of epithelial ovarian cancer (serous, mucinous, 
endometrioid and clear cell ovarian tumours). Additionally, serous ovarian tumours were 
categorised as either low- (grade 1) or high-grade (grade ≥2) serous tumours. A similar 
analytic approach was used to assess the association between cigarette smoking and 
progression-free survival. However, we only investigated the association between smoking 
status and progression-free survival for ovarian cancer overall and for serous ovarian tumours 
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because a limited number of cases impeded meaningful analyses for the remaining smoking 
variables and histotypes.  
 
In a stratified analysis, we investigated whether the association between smoking status and 
overall survival differed according to strata of stage of ovarian cancer at diagnosis (localised 
vs advanced stage). For this analysis, pairwise comparisons were made using t-tests based on 
estimates and standard errors from the stratified analyses and p-values were adjusted for 
multiple testing by use of the Bonferroni procedure. Finally, sensitivity analyses for the 
association between cigarette smoking and overall survival were performed where follow-up 
was restricted at ≤5, >5 - ≤10 and >10 years after the diagnosis of epithelial ovarian cancer. 
These sensitivity analyses were only conducted for ovarian cancer overall and for serous 
ovarian tumours, as small numbers of cases prohibited these analyses for the other histotypes. 
All p-values presented are two-sided. We used the statistical package meta in R (version 
3.1.0) for all analyses. 
 
RESULTS 
 
Detailed information on the 19 included case-control studies is shown in Table 1. Twelve 
studies were conducted in the United States, five in Europe and one each in Australia and 
Japan. The number of women diagnosed with epithelial ovarian cancer included in the studies 
varied from 33 (JPN) to 1,138 (USC). The age range at diagnosis varied from 19-93 years 
among women diagnosed between 1992 and 2012. Sixteen studies were population-based and 
three hospital-based (UKO, MAY and JPN). Eight studies (AUS, GER, JPN, MAY, SEA, 
TBO, UCI and UKO) involved information obtained from self-completed questionnaires, 
whereas 11 studies (CON, DOV, HAW, HOP, MAL, NCO, NEC, NJO, POL, STA and USC) 
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collected information by in-person interviews. Approximately 57% of the study women died 
during the follow-up period and 5-year survival was 48%. The median follow-up time was 7.0 
years.  
 
Among the 9,114 women with epithelial ovarian cancer, 54.5% were never smokers at 
diagnosis, 31.8% were former smokers, whereas current smokers constituted 13.7% of the 
study population (Table 2). Compared with never and former smokers, current smokers 
tended to be younger, were more often diagnosed with localised disease and with a mucinous 
or well-differentiated tumour. They were also more likely to be Black, were less obese, were 
less likely to have completed more than high school and more likely to have had residual 
disease compared with never and former smokers (all p-values <0.04).  
 
Figure 1 shows the association between cigarette smoking status and overall survival 
following a diagnosis of epithelial ovarian cancer, by study site (HRs) and overall (pHRs). In 
Table 3, the adjusted pHRs for the associations between the various smoking variables and 
overall survival after a diagnosis of epithelial ovarian cancer and according to histotype are 
presented. For women with epithelial ovarian cancer, both current (pHR = 1.17, 95% CI: 
1.08-1.28) (Table 3; Figure 1a) and former smokers (pHR = 1.10, 95% CI: 1.02-1.18) (Table 
3; Figure 1b) had a worse overall survival compared with women who had never smoked.  
In addition, an increasing number of cigarettes smoked per day and duration of smoking 
tended to have a negative impact on overall survival whereas increasing time since smoking 
cessation tended to have a positive impact on overall survival of epithelial ovarian cancer.  
 
Concerning the histotype-specific analyses, a number of associations are noteworthy. Both 
former (pHR = 1.12, 95% CI: 1.04-1.20) and current (pHR = 1.11, 95% CI: 1.00-1.23) 
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smokers diagnosed with serous ovarian tumours had a worse overall survival compared with 
never smokers (Table 3). Additional analyses stratified by grade revealed similar associations 
for women with high-grade (former smokers: pHR = 1.10, 95% CI: 1.02-1.18; current 
smokers: pHR = 1.11, 95% CI: 0.99-1.23) and low-grade serous ovarian tumours (former 
smokers: pHR = 1.43, 95% CI: 1.02-2.02; current smokers: pHR = 1.19, 95% CI: 0.80-1.78). 
The strongest associations were observed for mucinous ovarian tumours, where current 
smokers had a statistically significantly 91% worse survival (pHR = 1.91, 95% CI: 1.01-3.65) 
and former smokers a statistically non-significantly 43% worse survival (pHR = 1.43, 95% 
CI: 0.83-2.48) than never smokers. Also for this tumour type, an increasing number of 
cigarettes smoked per day tended to have a negative impact on survival (pHR = 1.10, 95% CI: 
0.95-1.26 per each additional 5 cigarettes smoked per day). In addition, current smokers with 
endometrioid ovarian tumours tended to have a poorer survival (pHR = 1.27, 95% CI: 0.91-
1.77), whereas no clear association between smoking status and overall survival was observed 
for clear cell tumours (Table 3). 
 
Potential confounders in the association between smoking and overall survival of ovarian 
cancer include BMI and level of education. Additional adjustment for these two variables in a 
model restricted to studies where this information was available (n = 15, Supplementary Table 
1) made virtually no changes to the estimated associations between smoking and overall 
survival, both when compared to results from the main statistical model (i.e., without 
adjustment for BMI and level of education) using data from these 15 studies only 
(Supplementary Table 2) and when compared with the results from the main statistical model 
using data from all 19 studies (Table 3). In addition, a statistical model including information 
on residual disease was also evaluated for the seven studies in which these data were 
available. In general, inclusion of this clinical variable did not result in any consistent changes 
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to the pooled estimates (Supplementary Table 3) when compared with results from the main 
statistical model including data from these seven studies only (Supplementary Table 4) and 
results from the main statistical model using data from all 19 studies (Table 3).  
 
For epithelial ovarian cancer and for serous ovarian tumours, we investigated whether the 
association between smoking status and overall survival varied by tumour stage (Table 4). 
Compared with never smokers, current smokers (pHR = 1.63, 95% CI: 1.19-2.22) with all 
histotypes of ovarian cancer combined had worse overall survival among women with 
localised stage disease. A significantly weaker association was observed with current smoking 
among women with advanced stage disease (pHR = 1.16, 95% CI: 1.06-1.28) (p-value for 
pairwise comparison = 0.04). The same pattern was seen for former smoking but the pooled 
HRs for former smokers were not statistically significantly different across tumour stage 
strata (p-value = 0.21). Comparable, but slightly higher pHRs were observed for serous 
ovarian tumours as former (pHR = 1.46, 95% CI: 0.87-2.45) and current smokers (pHR = 
1.67, 95% CI: 0.84-3.34) with localised disease had a poorer survival compared with never 
smokers. A less strong association was observed among women with advanced stage disease, 
but the pooled HRs for current and former smokers were not statistically significantly 
different across tumour stage strata (both p-values >0.05).  
 
We also examined the association between smoking and overall survival for epithelial ovarian 
cancer and for serous ovarian tumours according to follow-up time since ovarian cancer 
diagnosis (Table 5). Where follow-up was censored at 5 years after diagnosis, both former 
(pHR = 1.10, 95% CI: 1.02-1.18) and current smokers with ovarian cancer overall (pHR = 
1.17, 95% CI: 1.08-1.29) had a worse survival compared with never smokers. For the follow-
up period from >5 to ≤10 years after ovarian cancer diagnosis, similar patterns of survival 
Page 16 of 36
John Wiley & Sons, Inc.
International Journal of Cancer
This article is protected by copyright. All rights reserved.
 16 
 
were observed, although the pHRs did not reached statistical significance. Finally, for the 
follow-up period of >10 years after the ovarian cancer diagnosis, both former (pHR = 1.66, 
95% CI: 1.14-2.42) and current smokers (pHR = 2.54, 95% CI: 1.27-5.09) had a poorer 
survival compared with never smokers. For all follow-up periods, virtually similar survival 
patterns applied to women with serous ovarian tumours. For both ovarian cancer overall and 
for serous ovarian tumours, an increasing number of cigarettes smoked per day tended to have 
a negative impact on survival in the follow-up period of >10 years after the ovarian cancer 
diagnosis, whereas no association between number of cigarettes smoked per day and survival 
was found in follow-up ≤10 years since diagnosis. Also, increasing time since smoking 
cessation tended to have a positive impact on survival only when the length of the follow-up 
period exceeded 10 years, whereas no consistent pattern between duration of smoking and 
survival was noted with increasing follow-up time since diagnosis.     
 
Finally, we assessed the prognostic impact of smoking status on progression-free survival for 
ovarian cancer overall and for serous ovarian tumours in seven studies where this information 
was available. The pHRs resembled the results obtained for overall survival but the pHRs 
were not statistically significant, which may be explained by the relatively smaller numbers of 
women included for these analyses (data not shown).  
 
DISCUSSION 
 
To our knowledge, this is the largest study to date on cigarette smoking and epithelial ovarian 
cancer survival. We found that smoking status prior to diagnosis was associated with worse 
overall survival. Our results also showed that the association with smoking seemed to be 
different across histotypes of epithelial ovarian cancer being most pronounced for mucinous 
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tumours, where current smokers had an almost 2-fold worse survival compared with never 
smokers. Also, both former and current smoking was associated with worse survival 
following serous ovarian cancer (both for high-grade and low-grade serous tumours) and 
among current smokers with endometrioid ovarian tumours, whereas no appreciable 
relationships were observed for clear cell subtypes, though evaluation of this subtype was 
limited by small numbers. These associations remained virtually unchanged after additional 
adjustments for BMI, level of education and residual disease. Stratification by stage showed 
that smoking had a stronger association with overall survival among women with localised 
disease. Also, the magnitude of the association between smoking and overall survival 
appeared to increase with longer follow-up since ovarian cancer diagnosis. Finally, the results 
for progression-free survival resembled the results obtained for overall survival. 
 
Only seven previous studies, including between 61 and 1,997 study subjects, have 
investigated the association between smoking and epithelial ovarian cancer survival.
15-21
 
However, one of the studies was based on data from a study site (MAL) that is included in the 
present analysis and consequently, results from this study will not be discussed further.
15
 
While three previous studies found no marked association,
19-21
 the survival disadvantage 
associated with smoking observed in the present study is supported by the results from three 
other studies.
16-18
 For example, in a study of 676 women with epithelial ovarian cancer, Nagle 
et al.
16
 found that current smokers had 36% worse survival compared with non-smoking 
women and that worse survival was further increased with increasing number of pack-years 
and number of cigarettes smoked per day. Most recently, Kelemen et al.
18
 studied 432 
epithelial ovarian cancer patients receiving adjuvant chemotherapy from the Alberta Cancer 
Registry, Canada and while no association between smoking status and overall or 
progression-free survival among ovarian cancer overall was observed, histotype-specific 
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analyses showed that smoking women with mucinous ovarian tumours had worse overall and 
progression-free survival compared with non-smoking women. 
 
The observed associations between smoking and overall as well as histotype-specific ovarian 
cancer survivals may be explained by a number of mechanisms. It has been suggested that 
carcinogens in tobacco smoke directly accelerate tumour growth resulting in earlier 
progression and death. It has also been suggested that smoking is associated with an increased 
risk of recurrence, postsurgical complications, a poorer response to treatment and an increased 
treatment-related toxicity.
44,45
 Finally, smoking is known to be associated with an unhealthy 
lifestyle,
46
 which may have a negative effect on survival. 
 
We found that the association between smoking and survival observed for ovarian cancer 
overall was confined to the serous and especially mucinous histotypes of the disease and 
perhaps also to endometrioid tumours. Epidemiological studies have consistently found that 
the strongest association between smoking and risk of epithelial ovarian cancer appears to be 
with mucinous ovarian tumours,
8-11
 and the present results add further knowledge about the 
relationship between smoking and epithelial ovarian cancer. However, biological explanations 
for histotype-specific survival differences with regard to smoking are not known and should 
be investigated further.  
 
Our results suggested that current smoking may have a greater impact on survival among 
women with localised than disseminated disease. Further, we observed a tendency that 
smoking status was associated with an increasingly poorer survival with increasing follow-up. 
These results were observed both for ovarian cancer overall and for serous tumours, but 
evaluation of the other subtypes was hampered by small numbers. The results may reflect 
Page 19 of 36
John Wiley & Sons, Inc.
International Journal of Cancer
This article is protected by copyright. All rights reserved.
 19 
 
differences in stage. Women who are diagnosed in an advanced stage disease are more likely 
to die shortly after diagnosis, whereas women who survive for a longer time period are more 
likely to have been diagnosed in a localised stage. Thus, our results suggest that smoking has 
the most substantial impact on long-term survival, which most often occur among women 
diagnosed in an early stage. Our findings are not surprising given the poor prognosis among 
women with advanced stage disease, which leaves little potential for other factors including 
smoking to have an impact on ovarian cancer survival. 
 
A major strength of our study is the large sample size including more than 9,000 women with 
epithelial ovarian cancer, which allowed us to investigate associations between a number of 
variables of smoking and the various histotypes of epithelial ovarian cancer. For a subset of 
women, we also investigated progression-free survival and found no marked association, 
potentially due to insufficient power. We did not include ovarian cancer-specific survival 
analysis. However, among the limited cause of death data in our dataset, the vast majority 
died from ovarian cancer (94%) and we are thus confident that all-cause survival is a pertinent 
proxy for ovarian cancer survival. As the studies included in our pooled analysis were not 
selected from published studies, our analyses have not been affected by publication bias. Our 
analyses relied on individual data combined into a single dataset following careful central data 
harmonisation. By use of a two-stage approach, we were able to consider differences in study 
design and data collection across studies and to control for a number of potential confounders. 
Further, by utilising left truncated data, we decreased the likelihood of potential survivorship 
bias. Most importantly, adverse associations between smoking and survival were still 
observed after additional adjustment for BMI and level of education as well as the main 
clinical factors that affect survival: stage, grade and residual disease.  
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Women who smoke are known to have a higher degree of comorbidity compared with non-
smokers
47
 and comorbid conditions have a negative prognostic impact on survival from 
ovarian cancer.
48
 Specifically, women with comorbidities may not tolerate standard 
treatments and are therefore more often offered less aggressive types of treatment compared 
with healthier women.
49
 Unfortunately, we were not able to adjust for degree of comorbidity 
as this information was not available in our data at the time of analysis and we can therefore 
not rule out that our results may have been slightly affected by unmeasured confounding from 
comorbidity. However, as obesity and low socioeconomic status is highly associated with 
comorbidities,
50,51
 our adjustment for BMI and level of education may have diminished 
potential confounding by comorbidity. Further limitations of this study include the fact that 
information on smoking habits was based on retrospective reports in all studies included in 
the present paper, which increases the risk of misclassification, and that these reports of 
smoking behaviours pertained to time periods prior to diagnosis rather than to during follow-
up time. Newly diagnosed women with ovarian cancer could conceivably change their 
smoking behaviours and such information might not have been captured in the retrospective 
reporting. However, because the data on smoking were obtained independent of mortality 
events, any effects of possible misclassification are likely to be non-differential. In general, 
socially undesirable behaviours such as cigarette smoking may be prone to under-reporting, 
where current smokers may have categorised themselves as either never or former smokers 
and this may therefore have underestimated the true association between current smoking 
status and survival. In support of this idea, one study among others found that approximately 
one-third of newly diagnosed cancer patients who denied any current smoking had blood 
cotinine values at levels that supported active smoking.
52
 Another possible limitation of the 
present work is that in some studies ovarian tumours may not have undergone systematic 
histopathological review. Hence, some extent of misclassification of the histotypes cannot be 
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excluded. Finally, our study design did not allow us to investigate how smoking cessation 
after a diagnosis of epithelial ovarian cancer could affect survival.  
 
In conclusion, the results from this large pooled analysis indicate that cigarette smoking is 
associated with a worse survival in ovarian cancer patients; primarily among women 
diagnosed with serous and mucinous ovarian tumours. Furthermore, our results may also 
suggest that current smoking more strongly impairs survival among women with localised 
disease and that the effect of smoking on ovarian cancer prognosis increases with longer 
follow-up since ovarian cancer. Future studies are needed focusing on how smoking patterns 
after a diagnosis of ovarian cancer affect survival. 
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Table 1. Characteristics of the 19 case-control studies included in the pooled analysis of cigarette smoking and survival following a diagnosis of ovarian cancer 
Studya  Country 
Study 
period 
Cases 
(N) 
Age 
range at 
diagnosis 
Median follow-
up time among 
living (years) 
Number of 
women who 
died (%) 
5-year 
survival (%) 
AUS: Australian Ovarian Cancer Study & Australian Cancer Study28 Australia 2002-2006 1,007 20-80 7.1 629 (62.5) 482 (47.9) 
        
JPN: Hospital-based Research Programme at Aichi Cancer Center26 Japan 2001-2005 33 32-72 5.0 12 (36.4) 10 (30.3) 
   
GER: German Ovarian cancer study29 Germany 1993-1996 188 21-75 13.6 129 (68.6) 89 (47.3) 
   
MAL: The Danish Malignant Ovarian Tumor Study24 Denmark 1994-1999 516 32-80 13.5 393 (76.2) 226 (43.8) 
   
POL: Polish Ovarian Cancer Study33 Poland 2000-2003 171 32-74 5.2 90 (52.6) 55 (32.2) 
   
SEA: Study of Epidemiology and Risk Factors in Cancer Heredity35 United Kingdom 1998- 2010 582 23-74 6.2 279 (47.9) 309 (53.1) 
   
UKO: UK Ovarian Cancer Population Study32 United Kingdom 2006-2010 449 19-90 3.5 150 (33.4) 196 (43.7) 
   
CON: Connecticut Ovary Cancer Study40 USA 1998-2003 301 36-81 7.6 177 (58.8) 174 (57.8) 
   
DOV: Diseases of the Ovary and their Evaluation Study39 USA 2002-2005 462 35-74 6.4 256 (55.4) 251 (54.3) 
   
HAW: Hawaii Ovarian Cancer Case-Control Study25 USA 1993-2008 388 24-87 6.6 200 (51.5) 190 (49.0) 
   
HOP: Hormones and Ovarian Cancer Prediction Study38 USA 2003-2009 587 25-91 4.8 308 (52.5) 191 (32.5) 
   
MAY: Mayo Clinic Ovarian Cancer Case-Control Study27  USA 2000-2009 481 21-91 4.7 277 (57.6) 144 (29.9) 
   
NCO: North Carolina Ovarian Cancer study30 USA 1999-2008 833 22-74 6.9 496 (59.5) 354 (42.5) 
   
NEC: New England Case-Control Study of Ovarian Cancer31 USA 1992-2003 826 21-77 12.3 476 (57.6) 486 (58.8) 
   
NJO: New Jersey Ovarian Cancer Study23 USA 2002-2008 189 32-81 2.2 42 (22.2) 0 (0.0)b 
   
STA: Family Registry for Ovarian Cancer and Genetic Epidemiology of Ovarian Cancer34 USA 1997-2001 427 21-64 10.1 248 (58.1) 224 (52.5) 
   
TBO: Tampa Bay Ovarian Cancer Study41 USA 2000-2012 189 26-93 5.6 104 (55.0) 61 (32.3) 
   
USC: Los Angeles County Case-Control Studies of Ovarian Cancer38 USA 1993-2005 1,138 20-84 11.4 721 (63.4) 646 (56.8) 
   
UCI: University California, Irvine Ovarian Cancer Study37 USA 1993-2005 347 21-86 6.2 162 (46.7) 250 (72.0) 
        
TOTAL   1992-2012 9,114 19-93 7.0 5,149 (56.5) 4,338 (47.6) 
        
                                    a
All studies were population-based except for UKO, MAY and JPN that were all hospital-based.
 
                                    b
In the present study, no women included in NJO were followed for 5 years or more. Therefore, no women in NJO survived 5 years.
  
 
 
 
 
 
 
Page 30 of 36
John Wiley & Sons, Inc.
International Journal of Cancer
50
51
52
53
54
55
56
57
58
59
60
This article is protected by copyright. All rights reserved.
 30 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                   
 
 
 
  1No missing data 
  2Only seven studies provided information on residual disease (AUS, HAW, JPN, MAL, MAY, NCO and NEC) 
 
Table 2. Age distribution, covariate and clinical characteristics for the 9,114 women included in analysis, 
according to smoking status at diagnosis 
 
 
Smoking status 
 
 
Characteristics 
Never 
N (%) 
Former 
N (%) 
 Current 
N (%) 
Number of Women 4,966 (54.5)  2,900 (31.8)  1,248 (13.7) 
Age at diagnosis (years)1 
 
   
  <40 328  (6.6)  114 (3.9)  119  (9.5)  
  40-49 953  (19.2)  463 (16.0)  326  (26.1)  
  50-59 1,528  (30.8)  965 (33.3)  408  (32.7)  
  60-69 1,356  (27.3)  913 (31.5)  279  (22.4) 
  ≥70 801  (16.1)  445 (15.3)  116  (9.3) 
   
Tumour stage1 
 
   
  Localised 952  (19.2) 529 (18.2)  284  (22.8)  
  Regional 1,158  (23.3) 647 (22.3)  231  (18.5)  
  Distant 2,856  (57.5) 1,724 (59,4)  733  (58.7)  
   
Histology1 
 
   
  Serous 2,899  (58.3) 1,829 (63.1)  727  (58.3)  
    Serous low-grade  218  (4.4)  142 (4.9)  81  (6.5)  
    Serous high-grade 2,681  (54.0)  1,687 (58.2)  646  (51.8)  
  Mucinous 316  (6.4) 161 (5.6)  134  (10.7)  
  Endometrioid 839  (16.9) 460 (15.9)  174  (13.9) 
  Clear cell  374 (7.5) 150 (5.2) 
 
76  (6.1)  
  Other 538  (10.8) 300 (10.3)  137  (11.0)  
   
Grade1 
 
 
 
 
  Well differentiated 634  (12.8) 357 (12.3)  214  (17.1)  
  Moderately differentiated 1,286  (25.9) 709 (24.4)  317  (25.4)  
  Poorly differentiated 2,739  (55.2) 1,657 (57.1)  669  (53.6)  
  Undifferentiated 307  (6.2) 177 (6.1)  48  (3.8)  
   
Race/ethnicity1      
   
  Non-Hispanic White 4,187 (84.3)  2,629 (90.7)  1,108 (88.8)  
  Hispanic White 150 (3.0)  73 (2.5)  25 (2.0)  
  Black 103 (2.1)  71 (2.4)  60 (4.8)  
  Asian 369 (7.4)  59 (2.0)  18 (1.4)  
  Other 156 (3.1)  67 (2.3)  34 (2.7)  
         
BMI      
   
  Median  24.19  24.33  23.43 
  Interquartile range 21.48-28.34  21.64-28.59  20.90-27.48 
  Missing 359 (7.2)  217 (7.5)  52 (4.2) 
         
Level of education      
 
  
  ≤high school 2,168 (43.7)  1,275 (44.0)  771 (61.8)  
  >high school 2,621 (52.7)  1,516 (52.3)  438 (35.1)  
  Missing 177 (3.6)  109 (3.7)  39 (3.1) 
         
Residual disease2 
 
 
 
 
  No macroscopic disease present 539  (10.9) 255 (8.8)  128  (10.3)  
  Macroscopic disease present 714  (14.4) 420 (14.5)  214  (17.1)  
  Missing 3,713 (74.8)  2,225 (76.7)  906 (72.6) 
                            
Page 31 of 36
John Wiley & Sons, Inc.
International Journal of Cancer
This article is protected by copyright. All rights reserved.
 31 
 
Table 3. Adjusted pooled hazard ratios (pHRs) and 95% confidence intervals (CIs) for the association between cigarette smoking and overall survival among 9,114    
women from 19 studies with epithelial ovarian cancer, overall and by histotype 
 
Overall 
 
Serous 
 
Mucinous Endometrioid 
 
Clear cell 
  Cases I2 (%) pHR2 95% CI 
 
Cases I2 (%) pHR2 95% CI Cases I2 (%) pHR2 95% CI Cases I2 (%) pHR2 95% CI Cases I2 (%) pHR2 95% CI 
                         
Smoking status3 
 
 
 
   
  Never smoker4 4,966 - 1.00 Ref. 
 
2,899 - 1.00 Ref. 316 - 1.00 Ref. 835 - 1.00 Ref. 373 - 1.00 Ref. 
  Former smoker 2,900 17.6 1.10 (1.02-1.18) 
 
1,829 0.0 1.12 (1.04-1.20) 161 43.5 1.43 (0.83-2.48)1 460 33.3 0.85 (0.63-1.15) 150 8.1 1.17 (0.74-1.85) 
  Current smoker 1,248 0.0 1.17 (1.08-1.28) 
 
727 0.0 1.11 (1.00-1.23) 134 0.0 1.91 (1.01-3.65) 174 5.0 1.27 (0.91-1.77) 76 0.0 1.08 (0.67-1.75) 
      
Cigarette consumption 
(per day)5      
  1-≤10 1,630 0.0 1.12 (1.04-1.21) 1,016 0.0 1.16 (1.06-1.27) 103 0.0 1.46 (0.74-2.88) 248 21.1 0.78 (0.55-1.10) 85 0.0 0.78 (0.45-1.33) 
  >10-≤20 1,535 0.0 1.12 (1.03-1.21) 
 
922 0.0 1.08 (0.98-1.19) 124 16.5 1.69 (0.89-3.21) 227 58.9 1.17 (0.72-1.89)1 93 9.4 1.53 (0.93-2.51) 
  >20 615 10.9 1.24 (1.10-1.40) 
 
383 0.0 1.26 (1.10-1.43) 45 52.4 2.59 (0.59-10.89)1 100 42.2 1.28 (0.74-2.21) 22 0.0 1.23 (0.53-2.86) 
  Per 5 cigarettes/day6 0.0 1.01 (0.99-1.03) 
 
0.0 1.00 (0.98-1.02) 0.0 1.10 (0.95-1.26) 20.2 1.06 (0.98-1.14) 0.0 1.08 (0.94-1.24) 
      Duration of smoking 
before diagnosis7 
(years) 
 
 
    
  1-≤10 923 8.5 1.07 (0.97-1.19) 
 
565 0.0 1.10 (0.98-1.23) 53  NA10  156 34.4 0.96 (0.57-1.60) 48 0.0 1.80 (0.85-3.81) 
 >10-≤20 823 14.8 1.13 (1.00-1.26) 
 
504 0.0 1.15 (1.02-1.29) 64 0.0 1.52 (0.60-3.82) 132 0.0 0.73 (0.49-1.08) 42 0.0 1.29 (0.67-2.46) 
  >20 2,267 24.6 1.16 (1.06-1.25) 1,411 0.0 1.14 (1.06-1.24) 159 45.6 1.90 (0.71-5.05)1 322 36.7 1.05 (0.75-1.46) 126 6.4 1.09 (0.70-1.69) 
  Per 5-year period6  50.1 1.02 (1.00-1.04)1 
 
40.9 1.01 (0.99-1.04)1 22.4 0.95 (0.79-1.14) 27.3 1.05 (0.98-1.13)  9.4 1.04 (0.94-1.16) 
      
Time from cessation to 
diagnosis  (years)8  
 
    
  1-≤10 739 42.1 1.21 (1.04-1.40)1 
 
424 32.7 1.24 (1.05-1.47) 55 0.0 1.93 (0.84-4.42) 126 21.3 1.15 (0.73-1.81) 32 0.0 0.93 (0.37-2.37) 
  >10-≤20 599 0.0 1.22 (1.09-1.37) 
 
343 0.0 1.23 (1.07-1.41) 38 0.0 3.10 (0.99-9.72) 98 0.0 1.32 (0.86-2.03) 28 0.0 2.92 (1.13-7.54) 
  >20 1,086 0.0 1.08 (0.98-1.18) 
 
668 0.0 1.15 (1.03-1.28) 51 0.0 1.53 (0.69-3.39) 172 0.0 0.79 (0.55-1.13) 60 9.0 1.35 (0.67-2.74) 
  Per 5-year period9   32.7 0.97 (0.95-1.00) 
  
 22.7 0.98 (0.95-1.01)    0.0 0.96 (0.82-1.12)    0.0 0.98 (0.90-1.06)    0.0 0.93 (0.77-1.12) 
                         
Numbers may not sum up to total because of missing data 
1P-value for heterogeneity <0.05 
2Adjusted for: age (continuous), race/ethnicity (non-Hispanic White, Hispanic White, Black, Asian or other), tumour stage (localised, regional or distant) and grade (well differentiated, moderately differentiated, 
poorly differentiated or undifferentiated) 
3Number of studies included for analysis: overall = 19; serous = 19, mucinous = 15; endometrioid = 17; clear cell = 15 
4Never smokers was used as the reference group for all categorical analyses 
5Number of studies included for analysis: overall = 18; serous = 18, mucinous = 14; endometrioid = 16; clear cell = 14 
6Among ever smokers 
7Number of studies included for analysis: overall = 19; serous = 19, mucinous = 16; endometrioid = 17; clear cell = 15 
8Number of studies included for analysis: overall = 18; serous = 17, mucinous = 12; endometrioid = 15; clear cell = 14 
9Among former smokers only 
10Not applicable due to unreliable model parameters (small numbers of events) 
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 Table 4. Adjusted pooled hazard ratios (pHRs) and 95% confidence intervals (CIs) for the association between cigarette smoking status at diagnosis and overall  
 survival among 9,114 women from 19 studies diagnosed with epithelial ovarian cancer, overall and for serous ovarian tumours, stratified by stage 
 Overall   
 
Serous 
 
Localised stage  Advanced stage1  
 
Localised stage  Advanced stage1 
 
  Cases pHR2 95% CI  Cases pHR2 95% CI P-value 
 
Cases pHR2 95% CI  Cases pHR2 95% CI P-value 
           
Smoking status            
  Never 952 1.00 Ref.  4,014 1.00 Ref.  
 
182 1.00 Ref.  2,705 1.00 Ref. 
 
  Former 529 1.32 (0.96-1.82)  2,371 1.07 (1.00-1.15) 0.21 
 
134 1.46 (0.87-2.45)  1,689 1.09 (1.01-1.17) 0.27 
  Current 284 1.63 (1.19-2.22)  964 1.16 (1.06-1.28) 0.04 
 
56 1.67 (0.84-3.34)  665 1.09 (0.98-1.21) 0.23 
                   1Advanced stage includes regional and distant stage 
 2Adjusted for age (continuous), race/ethnicity (non-Hispanic White, Hispanic White, Black, Asian or other) and grade (well differentiated, moderately differentiated, poorly differentiated or undifferentiated) 
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  Table 5. Adjusted pooled hazard ratios (pHRs) and 95% confidence intervals (CIs) for the association between cigarette smoking and overall survival among 9,114    
  women from 19 studies diagnosed with epithelial ovarian cancer, overall and for serous ovarian tumours, according to length of follow-up since ovarian cancer    
  diagnosis 
   1Adjusted for age (continuous), race/ethnicity (non-Hispanic White, Hispanic White, Black, Asian or other), tumour stage (localised, regional or distant) and grade (well differentiated, moderately differentiated,    
   poorly differentiated or undifferentiated) 
   2Among ever smokers 
   3Among former smokers only 
 
 
 
 Length of follow-up 
 ≤5 years  >5 - ≤10 years  >10 years 
 Cases pHR1 95% CI  Cases pHR1 95% CI  Cases pHR1 95% CI 
            Overall epithelial ovarian cancer            
            
 Smoking status 9,114    4,308    1,419   
               Never 4,966 1.00 Ref.  2,425 1.00 Ref.  775 1.00 Ref. 
   Former 2,900 1.10 (1.02-1.18)  1,303 1.09 (0.95-1.25)  425 1.66 (1.14-2.42) 
   Current 1,248 1.17 (1.08-1.29)  580 1.13 (0.90-1.41)  219 2.54 (1.27-5.09) 
            
 Cigarette consumption (per day)            
   Per 5 cigarettes/day2  1.01 (0.99-1.03)   1.01 (0.96-1.05)   1.09 (0.95-1.25) 
            
 Duration of smoking before diagnosis (years)            
   Per 5-year period2  1.02 (1.00-1.04)   1.00 (0.97-1.04)   1.03 (0.95-1.12) 
            
 Time from cessation to diagnosis (years)            
   Per 5-year period3  0.97 (0.95-1.00)   0.97 (0.92-1.02)   0.90 (0.75-1.07) 
            
Serous ovarian tumours            
            
 Smoking status 5,455    2,117    583   
               Never 2,899 1.00 Ref.  1,173 1.00 Ref.  310 1.00 Ref. 
   Former 1,829 1.12 (1.04-1.20)  662 1.09 (0.93-1.29)  183 1.93 (1.15-3.23) 
   Current 727 1.11 (1.00-1.23)  282 1.02 (0.80-1.31)  90 1.88 (0.90-3.93) 
            
 Cigarette consumption (per day)            
   Per 5 cigarettes/day2  1.00 (0.98-1.02)   1.00 (0.94-1.05)   1.04 (0.91-1.19) 
            
 Duration of smoking before diagnosis (years)            
   Per 5-year period2  1.01 (0.99-1.04)   1.00 (0.96-1.04)   0.99 (0.88-1.12) 
            
 Time from cessation to diagnosis (years)            
   Per 5-year period3  0.98 (0.94-1.01)   1.00 (0.94-1.06)   0.87 (0.72-1.05) 
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FIGURE LEGENDS 
 
Figure 1. The association between cigarette smoking status at diagnosis and overall survival 
following a diagnosis of epithelial ovarian cancer, by study site and overall. Study-specific hazard 
ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox regression models 
adjusted for age, race/ethnicity, stage and grade. The pooled hazard ratio (pHR) with corresponding 
95% CI was estimated using a random effects model. a) Current versus never smokers; b) former 
versus never smokers.  
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MAY 1.41 (0.76 − 2.62) 1.94
GER 1.25 (0.68 − 2.31) 2.01
UKO 0.83 (0.46 − 1.49) 2.15
UCI 1.59 (0.91 − 2.78) 2.38
CON 0.87 (0.50 − 1.53) 2.41
POL 1.57 (0.90 − 2.73) 2.42
STA 1.14 (0.67 − 1.95) 2.66
HAW 1.18 (0.72 − 1.95) 2.99
SEA 1.07 (0.69 − 1.66) 3.90
DOV 1.17 (0.79 − 1.74) 4.83
HOP 1.47 (1.07 − 2.02) 7.40
NEC 1.29 (0.99 − 1.67) 11.19
NCO 0.95 (0.73 − 1.22) 11.63
MAL 1.16 (0.91 − 1.47) 12.72
AUS 1.24 (0.98 − 1.56) 13.58
USC 1.18 (0.93 − 1.49) 13.67
Site HR 95% CI Weight (%)
Pooled estimate 1.17 (1.08 − 1.28) 100
Heterogeneity: I
2
=0%, p=0.7854
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